Nvidia saw another surge on Friday following a significant increase triggered by strong earnings. The chip maker remains a standout on Wall Street, although UBS analyst Timothy Arcuri recently decided to lower his price target on the stock.
Stock Performance
- Nvidia shares were up by 2.1% in premarket trading at $801.50.
- The stock had risen by 16% the previous day, closing at $785.38 on Thursday.
Dominance in AI Hardware
Nvidia's dominance in providing hardware for artificial-intelligence systems has set it apart even from other leading stocks. Despite its impressive performance, some observers are keeping an eye out for any signs of a slowdown in its rapid growth.
Analyst Forecast and Target Price
UBS analyst Arcuri adjusted his target price on Nvidia to $800 from $850 post-earnings, noting a potential deceleration in revenue growth. However, he maintained a Buy rating on the stock. His revised target price was based on a 25 times price-to-earnings multiple of UBS' earnings forecast for Nvidia in 2025.
Analyst Insight
Arcuri expressed surprise over a slight decrease in total supply quarter-on-quarter, suggesting that Nvidia might be approaching a revenue "steady state" in the near future. He estimated that with no further supply increases, Nvidia could sustain revenue of approximately $27 billion per quarter.
Other Chip Maker Stocks
- Advanced Micro Devices showed a slight decline of 0.3% in premarket trading.
- Intel, on the other hand, was up by 0.6%.
Year-to-Date Performance
- Nvidia shares have already surged by 59% this year.
- In comparison, the S&P 500 index recorded a gain of 6.7% and the Nasdaq Composite Index increased by 6.9% over the same period.
For more information, contact Adam Clark.
Brambles Reports Strong Half-Year Results
Related Articles
Robinson's Debt Reduction Strategy
Robinson, a UK manufacturer, has sold surplus property and utilized pension funds to reduce debt. The company is also seeking new leadership.
Avalo Therapeutics Announces Sale of Assets to AUG Therapeutics
Avalo Therapeutics sees a boost in shares after selling assets to AUG Therapeutics. Deal terms include upfront payment and contingent milestone payments.
Boeing Reports Wider-Than-Expected Loss but Exceeds Revenue Expectations
Boeing reports a wider loss but exceeds revenue expectations, maintaining outlook for free cash flow. Stock performance declines. Categories: Business, Finance,...